Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 84811 | 2.26 |
09:34 ET | 27922 | 2.27 |
09:36 ET | 23411 | 2.24 |
09:38 ET | 6279 | 2.2692 |
09:39 ET | 17984 | 2.27 |
09:41 ET | 1693 | 2.2692 |
09:43 ET | 45260 | 2.2708 |
09:45 ET | 46343 | 2.2608 |
09:48 ET | 4570 | 2.27 |
09:50 ET | 39705 | 2.205 |
09:52 ET | 18096 | 2.175 |
09:54 ET | 21398 | 2.17 |
09:56 ET | 44416 | 2.21 |
09:57 ET | 2860 | 2.22 |
09:59 ET | 6621 | 2.245 |
10:01 ET | 4479 | 2.2408 |
10:03 ET | 11838 | 2.25 |
10:06 ET | 9781 | 2.2401 |
10:08 ET | 3472 | 2.26 |
10:10 ET | 13183 | 2.245 |
10:12 ET | 3967 | 2.255 |
10:14 ET | 4800 | 2.26 |
10:15 ET | 14776 | 2.26 |
10:17 ET | 7114 | 2.26 |
10:19 ET | 7292 | 2.245 |
10:21 ET | 4020 | 2.245 |
10:24 ET | 16744 | 2.235 |
10:26 ET | 3141 | 2.2309 |
10:28 ET | 24191 | 2.2107 |
10:30 ET | 30844 | 2.1905 |
10:32 ET | 10127 | 2.19 |
10:33 ET | 14760 | 2.2 |
10:35 ET | 1360 | 2.2 |
10:37 ET | 4784 | 2.2 |
10:39 ET | 7029 | 2.2 |
10:42 ET | 6854 | 2.2 |
10:44 ET | 9524 | 2.195 |
10:46 ET | 16419 | 2.21 |
10:48 ET | 2770 | 2.205 |
10:50 ET | 5549 | 2.205 |
10:51 ET | 8538 | 2.195 |
10:53 ET | 1625 | 2.1917 |
10:55 ET | 4874 | 2.195 |
10:57 ET | 3402 | 2.195 |
11:00 ET | 1600 | 2.2 |
11:02 ET | 29221 | 2.185 |
11:04 ET | 2917 | 2.19 |
11:06 ET | 18778 | 2.195 |
11:08 ET | 11253 | 2.1918 |
11:09 ET | 2372 | 2.2 |
11:11 ET | 3621 | 2.2 |
11:13 ET | 2551 | 2.205 |
11:15 ET | 4890 | 2.2093 |
11:18 ET | 1900 | 2.21 |
11:20 ET | 2050 | 2.21 |
11:22 ET | 9019 | 2.21 |
11:24 ET | 1688 | 2.21 |
11:26 ET | 6995 | 2.21 |
11:27 ET | 1983 | 2.21 |
11:29 ET | 2025 | 2.21 |
11:31 ET | 10706 | 2.23 |
11:33 ET | 8503 | 2.24 |
11:36 ET | 9896 | 2.22 |
11:38 ET | 6613 | 2.215 |
11:40 ET | 2012 | 2.22 |
11:42 ET | 1100 | 2.22 |
11:44 ET | 9146 | 2.235 |
11:45 ET | 10515 | 2.2292 |
11:47 ET | 2513 | 2.225 |
11:49 ET | 8010 | 2.22 |
11:51 ET | 5236 | 2.22 |
11:54 ET | 12895 | 2.215 |
11:56 ET | 15090 | 2.195 |
11:58 ET | 1400 | 2.2 |
12:00 ET | 1050 | 2.195 |
12:02 ET | 2828 | 2.2 |
12:03 ET | 1375 | 2.1992 |
12:05 ET | 9438 | 2.19 |
12:07 ET | 1501 | 2.1808 |
12:09 ET | 1304 | 2.185 |
12:12 ET | 3964 | 2.185 |
12:14 ET | 3827 | 2.1895 |
12:16 ET | 5936 | 2.185 |
12:18 ET | 1932 | 2.185 |
12:20 ET | 1983 | 2.185 |
12:21 ET | 14789 | 2.175 |
12:23 ET | 1907 | 2.175 |
12:25 ET | 7503 | 2.19 |
12:27 ET | 1381 | 2.19 |
12:30 ET | 2220 | 2.19 |
12:32 ET | 6704 | 2.185 |
12:34 ET | 1709 | 2.19 |
12:36 ET | 1900 | 2.19 |
12:38 ET | 15346 | 2.172 |
12:39 ET | 4108 | 2.175 |
12:41 ET | 25279 | 2.18 |
12:43 ET | 100 | 2.17 |
12:45 ET | 6210 | 2.175 |
12:48 ET | 1734 | 2.175 |
12:50 ET | 2532 | 2.18 |
12:52 ET | 1300 | 2.18 |
12:54 ET | 2371 | 2.1721 |
12:56 ET | 18928 | 2.19 |
12:57 ET | 4679 | 2.19 |
12:59 ET | 2126 | 2.19 |
01:01 ET | 15089 | 2.1792 |
01:03 ET | 967 | 2.18 |
01:06 ET | 11829 | 2.2 |
01:08 ET | 1967 | 2.2 |
01:10 ET | 18288 | 2.2 |
01:12 ET | 1372 | 2.21 |
01:14 ET | 3120 | 2.21 |
01:15 ET | 5172 | 2.205 |
01:17 ET | 10601 | 2.2 |
01:19 ET | 1157 | 2.2 |
01:21 ET | 2517 | 2.195 |
01:24 ET | 5980 | 2.21 |
01:26 ET | 2033 | 2.205 |
01:28 ET | 1837 | 2.21 |
01:30 ET | 23185 | 2.205 |
01:32 ET | 3343 | 2.2 |
01:33 ET | 3356 | 2.195 |
01:35 ET | 9132 | 2.185 |
01:37 ET | 900 | 2.185 |
01:39 ET | 6555 | 2.175 |
01:42 ET | 100 | 2.175 |
01:44 ET | 1725 | 2.18 |
01:46 ET | 5869 | 2.18 |
01:48 ET | 6600 | 2.19 |
01:50 ET | 1883 | 2.19 |
01:51 ET | 5405 | 2.19 |
01:53 ET | 2027 | 2.19 |
01:55 ET | 9721 | 2.2 |
01:57 ET | 13105 | 2.2 |
02:00 ET | 17594 | 2.2 |
02:02 ET | 1000 | 2.2 |
02:04 ET | 7736 | 2.21 |
02:06 ET | 1928 | 2.21 |
02:08 ET | 9287 | 2.195 |
02:09 ET | 19055 | 2.195 |
02:11 ET | 900 | 2.1917 |
02:13 ET | 12317 | 2.1814 |
02:15 ET | 5050 | 2.19 |
02:18 ET | 3601 | 2.185 |
02:20 ET | 5862 | 2.2 |
02:22 ET | 1879 | 2.2 |
02:24 ET | 2315 | 2.1992 |
02:26 ET | 2836 | 2.2 |
02:27 ET | 3153 | 2.2 |
02:29 ET | 4060 | 2.2 |
02:31 ET | 3265 | 2.2 |
02:33 ET | 3200 | 2.2 |
02:36 ET | 2767 | 2.2 |
02:38 ET | 3677 | 2.2 |
02:40 ET | 2194 | 2.2 |
02:42 ET | 3378 | 2.2 |
02:44 ET | 1772 | 2.2 |
02:45 ET | 2019 | 2.194 |
02:47 ET | 12376 | 2.2 |
02:49 ET | 3706 | 2.2 |
02:51 ET | 2400 | 2.2 |
02:54 ET | 2796 | 2.1975 |
02:56 ET | 3213 | 2.2 |
02:58 ET | 25832 | 2.1925 |
03:00 ET | 2500 | 2.185 |
03:02 ET | 1500 | 2.19 |
03:03 ET | 2669 | 2.19 |
03:05 ET | 8788 | 2.2 |
03:07 ET | 3815 | 2.21 |
03:09 ET | 1540 | 2.21 |
03:12 ET | 4189 | 2.205 |
03:14 ET | 2431 | 2.21 |
03:16 ET | 3481 | 2.21 |
03:18 ET | 2175 | 2.2077 |
03:20 ET | 5957 | 2.21 |
03:21 ET | 5452 | 2.22 |
03:23 ET | 25747 | 2.2099 |
03:25 ET | 2651 | 2.205 |
03:27 ET | 8099 | 2.2 |
03:30 ET | 3151 | 2.205 |
03:32 ET | 5707 | 2.205 |
03:34 ET | 11537 | 2.2 |
03:36 ET | 32510 | 2.185 |
03:38 ET | 23689 | 2.195 |
03:39 ET | 10103 | 2.205 |
03:41 ET | 8099 | 2.21 |
03:43 ET | 13034 | 2.21 |
03:45 ET | 11075 | 2.21 |
03:48 ET | 21363 | 2.195 |
03:50 ET | 9481 | 2.19 |
03:52 ET | 14130 | 2.195 |
03:54 ET | 15786 | 2.195 |
03:56 ET | 23085 | 2.195 |
03:57 ET | 104457 | 2.175 |
03:59 ET | 247915 | 2.16 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 146.9M | -2.0x | --- |
Organogenesis Holdings Inc | 383.1M | 66.5x | --- |
Amarin Corporation PLC | 308.6M | -5.8x | --- |
Coherus BioSciences Inc | 189.3M | -2.1x | --- |
Sinovac Biotech Ltd | 639.9M | -6.0x | --- |
Puma Biotechnology Inc | 176.6M | 11.4x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $146.9M |
---|---|
Revenue (TTM) | $398.0M |
Shares Outstanding | 68.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.07 |
Book Value | $6.40 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 0.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.